Suk Kyun Hong, Minseob Kim, Youngjin Kim, Jae-Yoon Kim, Jaewon Lee, Jiyoung Kim, Su Young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh. Ann Hepatobiliary Pancreat Surg 2024;28:337-43. https://doi.org/10.14701/ahbps.24-020
Suk Kyun Hong, Minseob Kim, Youngjin Kim, Jaeyoon Kim, Hyun Hwa Choi, Jaewon Lee, Jiyoung Kim, Su young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh. Ann Liver Transplant -0001;0:. https://doi.org/10.52604/alt.23.0010
Background/Objectives: Postoperative nausea and vomiting (PONV) remain frequent after breast surgery despite prophylaxis. This single-center, parallel-group randomized controlled trial evaluated whether intraoperative opioid-sparing anesthesia using dexmedetomidine and lidocaine reduced 48 h PONV compared with opioid-based anesthesia. Methods: Adult women undergoing elective breast surgery were randomized 1:1 to opioid-sparing anesthesia with dexmedetomidine and lidocaine or conventional opioid-based anesthesia with remifentanil. Participants and postoperative outcome assessors were blinded to group allocation; attending anesthesiologists were not blinded. All patients received standardized sevoflurane anesthesia, dexamethasone, ramosetron, quantitative neuromuscular monitoring, and postoperative fentanyl patient-controlled analgesia. The primary outcome was PONV within 48 h after surgery. Results: Among 68 randomized patients, 67 were analyzed (opioid-sparing group, n = 33; control group, n = 34). PONV within 48 h occurred in 8 patients (24.2%) in the opioid-sparing group and 28 patients (82.4%) in the control group (risk ratio, 0.29; 95% confidence interval, 0.16–0.55; p < 0.001; absolute risk reduction, 58.1%; number needed to treat, 1.7). Rescue antiemetic use was lower in the opioid-sparing group in the postanesthesia care unit and at 1 h postoperatively. Pain scores and cumulative opioid consumption were comparable. No Clavien–Dindo grade III or higher complications occurred. Conclusions: Intraoperative opioid-sparing anesthesia was associated with lower 48 h PONV after breast surgery without apparent compromise in analgesia. These single-center findings, from a trial registered after enrollment of one participant, require confirmation in larger prospectively registered multicenter trials. Trial Registration: Clinical Research Information Service (CRIS), KCT0009829. Registered on 10 October 2024.
30 November 2023 in Annals of Liver Transplantation
Suk Kyun Hong, Minseob Kim, Youngjin Kim, Jae-Yoon Kim, Jaewon Lee, Jiyoung Kim, Su young Hong, Jeong-Moo Lee, YoungRok Choi, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh. Ann Liver Transplant 2023;3:94-9. https://doi.org/10.52604/alt.23.0015
1 January 2026 in Journal of Metabolic and Bariatric Surgery
Metabolic and bariatric surgery (MBS) is an effective treatment for severe obesity and its related comorbidities. However, the long-term success and safety of these procedures depend heavily on continuous postoperative follow-up. Postoperative follow-up during the first year is essential for detecting surgical complications, monitoring weight loss trajectories, and optimizing nutritional status. Long-term follow-up is equally important for preventing weight regain, micronutrient deficiencies and recurrence of metabolic diseases. Structured and lifelong follow-up is a fundamental component of successful MBS. Despite recommendations from international societies, adherence to structured follow-up remains inconsistent in real-world practice. This review summarizes current evidence on optimal follow-up strategies after MBS, focusing on nutritional monitoring, management of complications, metabolic surveillance, psychosocial support, and multidisciplinary care.